undamentalytics Newsletter
Sign in

Alnylam Pharmaceuticals, Inc. cash flow statement

In fiscal 2025, Alnylam Pharmaceuticals, Inc.'s operations generated $524m of cash; it spent $58.7m on capital projects, leaving free cash flow of $465m.

Cash flow statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2008Dec 20082009Dec 20092010Dec 20102016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025
Cash from operations65−72−84−308−383−563−278−615−642−541104−8524
Depreciation and amortisation66515131517354844545756
Stock-based pay1820197693158175140166231222272348
Capital spending115565104127140707672623459
Free cash flow55−77−89−372−487−690−419−685−718−61342−43465
Free cash flow after stock pay37−97−108−448−580−847−593−825−884−844−180−315117
Shares issued511—1,140038200————

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

Compare with peers

Head to head: ALNY vs NBIXALNY vs BMRNALNY vs ARGX

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Alnylam Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Alnylam Pharmaceuticals, Inc.